Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe page revision indicator changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter/site metadata updated: Revision v3.3.3 added; HHS Vulnerability Disclosure link removed and Revision v3.3.2 removed, with no impact on study content or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page shows an updated revision from v3.3.1 to v3.3.2, indicating a minor update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded revision label v3.3.1 and removed revision label v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedFunding-status notice at the bottom of the page was removed. The core study content, including objectives, eligibility criteria, and outcome measures, remains unchanged.SummaryDifference0.4%

- Check76 days agoChange DetectedNo significant changes detected between the two page states; only minor visual differences are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.